Biofil Chemicals & Pharmaceuticals Ltd
Incorporated in 1993, Biofil Chemicals and Pharmaceuticals Ltd deals in Pharmaceuticals and Chemicals products.[1]
- Market Cap ₹ 59.0 Cr.
- Current Price ₹ 36.2
- High / Low ₹ 50.9 / 25.6
- Stock P/E 21.1
- Book Value ₹ 13.2
- Dividend Yield 0.00 %
- ROCE 15.8 %
- ROE 13.8 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Stock is trading at 2.74 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -4.50% over past five years.
- Company has a low return on equity of 7.20% over last 3 years.
- Earnings include an other income of Rs.3.08 Cr.
- Company has high debtors of 355 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.86 | 13.17 | 13.45 | 12.36 | 23.13 | 29.69 | 35.75 | 22.38 | 30.04 | 40.04 | 33.40 | 28.40 | |
| 5.12 | 12.30 | 10.84 | 11.43 | 22.11 | 27.87 | 34.15 | 21.05 | 28.88 | 39.23 | 32.55 | 27.75 | |
| Operating Profit | 0.74 | 0.87 | 2.61 | 0.93 | 1.02 | 1.82 | 1.60 | 1.33 | 1.16 | 0.81 | 0.85 | 0.65 |
| OPM % | 12.63% | 6.61% | 19.41% | 7.52% | 4.41% | 6.13% | 4.48% | 5.94% | 3.86% | 2.02% | 2.54% | 2.29% |
| 0.46 | 0.53 | 0.14 | 0.10 | 0.10 | 0.17 | 0.80 | 0.15 | 0.10 | 0.49 | 0.31 | 3.08 | |
| Interest | 0.21 | 0.15 | 0.16 | 0.15 | 0.16 | 0.12 | 0.07 | 0.04 | 0.04 | 0.04 | 0.04 | 0.01 |
| Depreciation | 0.25 | 0.26 | 0.28 | 0.30 | 0.37 | 0.41 | 0.41 | 0.43 | 0.43 | 0.40 | 0.38 | 0.27 |
| Profit before tax | 0.74 | 0.99 | 2.31 | 0.58 | 0.59 | 1.46 | 1.92 | 1.01 | 0.79 | 0.86 | 0.74 | 3.45 |
| Tax % | 20.27% | 20.20% | 22.51% | 20.69% | 20.34% | 17.81% | 34.90% | 31.68% | 29.11% | 17.44% | 24.32% | 19.42% |
| 0.59 | 0.78 | 1.79 | 0.47 | 0.48 | 1.21 | 1.24 | 0.70 | 0.56 | 0.71 | 0.56 | 2.79 | |
| EPS in Rs | 0.36 | 0.48 | 1.10 | 0.29 | 0.29 | 0.74 | 0.76 | 0.43 | 0.34 | 0.44 | 0.34 | 1.71 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | -5% |
| 3 Years: | -2% |
| TTM: | -15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 18% |
| 3 Years: | 71% |
| TTM: | 398% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | -12% |
| 3 Years: | -7% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | 7% |
| Last Year: | 14% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 |
| Reserves | -7.86 | -5.37 | -3.58 | -3.11 | -2.62 | -1.39 | -0.14 | 0.56 | 1.03 | 1.93 | 2.51 | 5.29 |
| 2.98 | 1.37 | 1.43 | 1.56 | 1.64 | 1.19 | 0.43 | 0.46 | 0.52 | 0.44 | 0.47 | 3.02 | |
| 2.36 | 11.87 | 7.72 | 9.44 | 8.93 | 26.30 | 16.68 | 1.44 | 13.58 | 28.44 | 31.70 | 18.27 | |
| Total Liabilities | 13.75 | 24.14 | 21.84 | 24.16 | 24.22 | 42.37 | 33.24 | 18.73 | 31.40 | 47.08 | 50.95 | 42.85 |
| 9.06 | 8.98 | 9.16 | 9.25 | 10.29 | 10.09 | 9.78 | 9.42 | 9.00 | 8.62 | 8.34 | 6.94 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 4.69 | 15.16 | 12.68 | 14.91 | 13.93 | 32.28 | 23.46 | 9.31 | 22.40 | 38.46 | 42.61 | 35.91 | |
| Total Assets | 13.75 | 24.14 | 21.84 | 24.16 | 24.22 | 42.37 | 33.24 | 18.73 | 31.40 | 47.08 | 50.95 | 42.85 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.14 | 0.71 | 0.46 | 1.26 | 0.89 | 1.11 | -0.22 | -0.11 | 2.39 | -1.92 | -0.60 | |
| -0.17 | -0.19 | -0.48 | -0.38 | -1.41 | -0.21 | -0.10 | -0.07 | -0.01 | -0.02 | -0.10 | 1.14 | |
| 0.11 | 0.10 | -0.11 | -0.02 | -0.08 | -0.57 | -0.83 | -0.01 | 0.02 | -0.12 | 0.00 | 2.54 | |
| Net Cash Flow | -0.05 | 0.05 | 0.13 | 0.06 | -0.24 | 0.12 | 0.18 | -0.30 | -0.11 | 2.25 | -2.03 | 3.07 |
| Free Cash Flow | -0.16 | -0.05 | 0.23 | 0.08 | -0.15 | 0.68 | 1.01 | -0.29 | -0.12 | 2.37 | -2.02 | 0.54 |
| CFO/OP | 19% | 33% | 35% | 103% | 134% | 63% | 112% | 8% | 10% | 314% | -205% | 9% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 227.35 | 387.45 | 311.00 | 383.31 | 189.84 | 365.25 | 175.81 | 116.94 | 249.08 | 301.10 | 418.77 | 354.59 |
| Inventory Days | 15.99 | 3.46 | 7.29 | 38.11 | 21.73 | 24.37 | 48.85 | 24.20 | 16.11 | 24.81 | 39.52 | 56.24 |
| Days Payable | 198.49 | 400.98 | 304.52 | 341.46 | 156.66 | 373.80 | 178.39 | 11.25 | 168.39 | 268.08 | 366.66 | 239.87 |
| Cash Conversion Cycle | 44.85 | -10.07 | 13.76 | 79.95 | 54.90 | 15.82 | 46.27 | 129.88 | 96.80 | 57.83 | 91.63 | 170.96 |
| Working Capital Days | -47.96 | 48.50 | 87.65 | 104.83 | 50.81 | 55.69 | 64.12 | 125.25 | 104.25 | 69.37 | 114.09 | 152.17 |
| ROCE % | 8.59% | 9.64% | 18.72% | 5.06% | 5.00% | 10.08% | 12.20% | 6.20% | 4.73% | 4.94% | 4.12% | 15.79% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtors’ Turnover Ratio times |
|
||||||||||
| Total Number of Permanent Employees number |
|||||||||||
| Total Industrial Land (Pithampur) sq. meters |
|||||||||||
| Unutilized Industrial Land (Pithampur) sq. meters |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1 Jun - Submission of publication of Audited Financial Results in the Newspaper pursuant to Regulation 47 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015
- Audited Financial Result For The Financial Year Ended 31.03.2026 30 May
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday 30Th May, 2026 Pursuant To Regulation 30 Of SEBI (LODR) Regulations, 2015.
30 May - Board approved audited FY26 results on 30 May 2026; revenue ₹2,839.52 lakh, profit ₹278.60 lakh.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
23 May - Submitted FY2026 secretarial compliance report; disclosed fines for delayed CS appointment and board composition, appeal pending.
-
Board Meeting Intimation for Meeting Of Board Of The Directors (Serial No.01/2026-27) Of The Company Scheduled To Be Held On Saturday, 30Th May, 2026.
21 May - Board meets 30 May 2026 to approve audited FY2026 results; trading window opens 48 hours later.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
BCPL is engaged in diverse pharmaceutical activities including manufacture and trading
of various pharmaceutical and chemical products. It also deals in providing job work facility in respect of manufacturing of pharmaceuticals drug. The company runs its business via 2 units viz. Pharmaceutical Division & Chemicals Division.